# Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma

> **NCT02221492** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 32 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** plerixafor GZ316455
- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT02221492
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2016-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02221492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02221492, "Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02221492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*